{"filing":{"accession_number":"0001434265-26-000138","cik":"0001434265","ticker":"GNMSF","company_name":"GENMAB A/S","form":"6-K","filing_date":"2026-10-23","report_date":"2026-10-23","primary_document":"gmab_20261023x6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1434265/000143426526000138/gmab_20261023x6k.htm"},"events":[{"id":37515,"run_id":34577,"accession_number":"0001434265-26-000138","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This announcement discloses positive Phase 3 clinical trial results for rinatabart sesutecan (Rina-S®) in platinum-resistant ovarian cancer, meeting primary and key secondary endpoints (PFS and OS with statistically significant improvements). While this is a material clinical milestone for a biotech company's pipeline advancement and regulatory pathway, it does not fit the discrete event categories (not an earnings release, M\u0026A, executive change, or financial obligation). The disclosure is clearly operational/strategic—a major product development milestone—making `operational_other` the most appropriate classification for a material clinical trial success that will inform regulatory discussions and future commercialization strategy.","company_name":"GENMAB A/S","ticker":"GNMSF","filing_date":"2026-10-23","form":"6-K","submitted_at":null,"items":[{"id":42250,"accession_number":"0001434265-26-000138","item_number":"EX-99.1","item_title":"gmab_20261023xex99d1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This announcement discloses positive Phase 3 clinical trial results for rinatabart sesutecan (Rina-S®) in platinum-resistant ovarian cancer, meeting primary and key secondary endpoints (PFS and OS with statistically significant improvements). While this is a material clinical milestone for a biotech company's pipeline advancement and regulatory pathway, it does not fit the discrete event categories (not an earnings release, M\u0026A, executive change, or financial obligation). The disclosure is clearly operational/strategic—a major product development milestone—making `operational_other` the most appropriate classification for a material clinical trial success that will inform regulatory discussions and future commercialization strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-23T15:59:38.786428+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":42250,"accession_number":"0001434265-26-000138","item_number":"EX-99.1","item_title":"gmab_20261023xex99d1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This announcement discloses positive Phase 3 clinical trial results for rinatabart sesutecan (Rina-S®) in platinum-resistant ovarian cancer, meeting primary and key secondary endpoints (PFS and OS with statistically significant improvements). While this is a material clinical milestone for a biotech company's pipeline advancement and regulatory pathway, it does not fit the discrete event categories (not an earnings release, M\u0026A, executive change, or financial obligation). The disclosure is clearly operational/strategic—a major product development milestone—making `operational_other` the most appropriate classification for a material clinical trial success that will inform regulatory discussions and future commercialization strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-23T15:59:38.786428+00:00","company_name":"GENMAB A/S","ticker":"GNMSF","filing_date":"2026-10-23"}]}